Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
29/07/2026 13:31
BRIEF-Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀ July 29 (Reuters) - PolyPid Ltd PYPD.O:
POLYPID ANNOUNCES FDA ACCEPTANCE OF NDA WITH PRIORITY REVIEW FOR D-PLEX₁₀₀
POLYPID - FDA SETS PDUFA TARGET ACTION DATE OF NOVEMBER 28, 2026 FOR D-PLEX100
POLYPID - FDA ACCEPTANCE TRIGGERS $15 MILLION MILESTONE PAYMENT, COMPLETING $30 MILLION IN PAYMENTS
Source text: ID:nGNX7LNwMF
Further company coverage: PYPD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA